146.98MMarket Cap-3164P/E (TTM)
2.700High2.600Low144.50KVolume2.690Open2.640Pre Close384.02KTurnover0.51%Turnover RatioLossP/E (Static)54.64MShares5.83052wk High1.94P/B76.96MFloat Cap0.36352wk Low--Dividend TTM28.61MShs Float16.220Historical High--Div YieldTTM3.79%Amplitude0.363Historical Low2.657Avg Price1Lot Size
Elevation Oncology Stock Forum
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
A quick recap for the month ending April 30, 2024.
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
No comment yet